News

Abzena announces location of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors

Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of[...] Read more

Sonnet BioTherapeutics selects Abzena as clinical stage manufacturing partner for its IL-12-FHAB cytokine-derived therapeutic candidate

PRINCETON, NJ and San Diego, CA, USA 22 October 2019 – Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical[...] Read more

Abzena announces 14-month cell line to phase 1 GMP service and appointment of Shahram Katousian as Head of biologics manufacturing

San Diego, USA, 3 June 2019 – Abzena, the leading biotherapeutics target to GMP partner research organization (PRO)[...] Read more

Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO),[...] Read more

Abzena and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases

  San Diego, USA, 19 March 2019 – Abzena, the global biologics gene to GMP partner research organization, announced[...] Read more

ABZENA ANNOUNCES APPOINTMENT OF ELAINE SAPINOSO AS GLOBAL HEAD OF QUALITY

Addition of experienced leadership in GMP Quality as Abzena increases capacity in biologics and complex small molecule[...] Read more

Abzena Announces Expansion of Integrated Biologics Offering with the Addition of Preformulation and Formulation Capability

Dr. Jonathan Goldman, CEO, Abzena, announced that Abzena has augmented existing discovery to GMP drug substance and[...] Read more

Abzena announces 20m$ investment into expansion of integrated biotherapeutics offering (Biologics Drug Substance and ADC) and makes key executive appointment

Significant increase in capacity to 2000 L scale in new GMP facility, addition of extra cell line development capacity[...] Read more

Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)

Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA[...] Read more

Abzena and Telix sign strategic manufacturing and bioconjugation agreement

Cambridge, UK and Melbourne, Australia, 2 July 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group[...] Read more

Abzena announces location of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors

Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of[...] Read more

Interested in our services? Get In Touch